What is the lowest creatinine clearance at which Fosamax (alendronate) can be safely administered to a patient with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lowest Creatinine Clearance for Fosamax

Fosamax (alendronate) is not recommended for patients with creatinine clearance less than 35 mL/min. 1

FDA-Approved Threshold

The FDA drug label explicitly states that alendronate sodium is contraindicated in patients with creatinine clearance below 35 mL/min 1. This represents the official regulatory cutoff for safe administration.

Clinical Evidence Supporting This Threshold

Guideline Recommendations

  • The ACOG practice bulletin on osteoporosis lists alendronate dosing for prevention and treatment but does not specify renal dosing adjustments, implicitly supporting the FDA threshold 2
  • Bisphosphonate guidelines for multiple myeloma note that zoledronic acid (a related bisphosphonate) requires dose reduction for creatinine clearance 30-49 mL/min, with the highest risk of renal deterioration occurring in patients with creatinine clearance 30-49 mL/min (32.1% vs 7.7% in placebo) 2

Real-World Safety Data

  • A 2013 systematic review of renal safety in bisphosphonate-treated osteoporosis patients confirmed that all oral bisphosphonates, including alendronate, carry warnings or contraindications for use in patients with severe renal impairment (creatinine clearance <30 or <35 mL/min) 3
  • A 2021 retrospective cohort study examined alendronate use in older patients (>65 years) with creatinine clearance <35 mL/min and found no significant deterioration in renal function compared to controls, though this study was not powered to definitively establish safety 4

Important Clinical Considerations

Why This Threshold Exists

Bisphosphonates are renally excreted, and impaired renal function can lead to drug accumulation and increased risk of nephrotoxicity 3. The 35 mL/min cutoff represents the point below which safety data from pivotal trials becomes insufficient 1.

Common Pitfalls to Avoid

  • Failure to calculate creatinine clearance: A 2003 study of skilled nursing facilities found that 38.5% of patients on alendronate had no documented serum creatinine, and 51.3% of those with calculable values had creatinine clearance <35 mL/min, indicating widespread inappropriate prescribing 5
  • Using serum creatinine alone: Always calculate creatinine clearance using the Cockcroft-Gault equation, as serum creatinine alone is unreliable, especially in elderly patients 5
  • Ignoring age-related renal decline: Elderly patients often have reduced renal function despite "normal" serum creatinine due to decreased muscle mass 5

Monitoring Requirements

If alendronate is used in patients with creatinine clearance near the threshold (35-50 mL/min), close monitoring of renal function is essential, as even oral bisphosphonates can rarely cause acute kidney injury or proteinuria 6.

Alternative Considerations

For patients with creatinine clearance <35 mL/min who require osteoporosis treatment, consider alternative agents such as denosumab (Prolia), which does not require renal dose adjustment and is not contraindicated in severe renal impairment 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013

Research

Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021

Related Questions

What osteoporosis medications are safe for patients with severe impaired renal function (Creatinine Clearance < 35 milliliters per minute)?
Is Alendronate (alendronate sodium) 70 mg safe with impaired renal function, specifically an estimated glomerular filtration rate (eGFR) of 56?
Is alendronate (bisphosphonate) contraindicated in an 83-year-old female with osteoporosis, impaired renal function (GFR 31, creatinine (crea) 1.75), and a history of breast cancer?
What is the recommended treatment for a 73-year-old male with moderate fracture risk due to osteoporosis based on Bone Mineral Density (BMD)?
What is the ICD-10 code for a patient with severe osteoporosis, as indicated by a bone density study showing a T-score of -4.55 in the spine and -2.63 in the femoral neck, with a history of rheumatoid arthritis, stage 3b chronic kidney disease (CKD), and history of falls, who is prescribed alendronate and potentially an anabolic agent?
How do you work up a patient with nausea?
What is the significance of a urine albumin to creatinine (ACR) ratio of 1912 and how should it be managed in a patient with potential pre-existing conditions such as diabetes or hypertension?
What are the risks and best treatment approaches for a patient in their 30s with a family history of paternal prostate cancer, taking 30mg Adderall XR (dextroamphetamine and amphetamine), who wants to start feminizing hormone replacement therapy (HRT)?
What is the best course of treatment for a patient presenting with vestibular disturbance?
What is the best treatment approach for a 50-year-old male with mild multilevel degenerative changes of the lumbar spine, back pain, and no apparent acute abnormality?
Can serrapeptase increase the risk of thrombosis, particularly in patients with a history of cardiovascular disease or those at risk for thrombosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.